We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+14.45%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$128M
AUM Growth
+$10.1M
Cap. Flow
+$3.44M
Cap. Flow %
2.69%
Top 10 Hldgs %
70.42%
Holding
59
New
8
Increased
11
Reduced
8
Closed
1

Top Buys

Rank Stock Value
1
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$1.1M
2
PHR icon
Phreesia
PHR
+$552K
3
STOK icon
Stoke Therapeutics
STOK
+$534K
4
TXG icon
10x Genomics
TXG
+$392K
5
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$315K

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$735K
2
INBX
Inhibrx, Inc. Common Stock
INBX
+$471K
3
BLUE
bluebird bio
BLUE
+$408K
4
TSVT
2seventy bio
TSVT
+$123K
5
KPTI icon
Karyopharm Therapeutics
KPTI
+$91.6K

Sector Composition

Rank Sector Weight
1 Healthcare 95.37%
2 Energy 4.62%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CSTL icon
51
Castle Biosciences
CSTL
$725M
$216K 0.17%
+10,000
New +$176K
WVE icon
52
Wave Life Sciences
WVE
$1.1B
$202K 0.16%
+40,000
New +$214K
GOSS icon
53
Gossamer Bio
GOSS
$71.2M
$126K 0.1%
138,176
-70,912
-34% -$52.4K
BCRX icon
54
BioCryst Pharmaceuticals
BCRX
$2.34B
$120K 0.09%
20,000
– –
TSVT
55
DELISTED
2seventy bio
TSVT
$84.7K 0.07%
19,833
-40,000
-67% -$123K
IFRX icon
56
InflaRx
IFRX
$270M
$81.5K 0.06%
50,000
– –
VTYX
57
DELISTED
Ventyx Biosciences
VTYX
$71.1K 0.06%
28,800
+2,400
+9% +$22.8K
YTEN
58
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$4.49K ﹤0.01%
781
– –
NKTR icon
59
Nektar Therapeutics
NKTR
$2.22B
– –
-1,867
Closed -$16.7K
1 2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q4 2023 Portfolio in Review

As of Q4 2023, Birchview Capital held 59 positions worth $128M, up 8.6% from $118M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Birchview Capital's Q4 2023 filing shows 8 new, 11 increased, 8 reduced and 1 closed positions. Its largest new stake was Biohaven Pharmaceutical Holding Company Ltd.: 7,365 shares worth $315K. The largest sale was Bristol-Myers Squibb, an estimated $735K.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q4 2023 buy was Biohaven Pharmaceutical Holding Company Ltd.: 7,365 shares worth $315K.
  • Birchview Capital added most to Silk Road Medical, Inc. Common Stock in Q4 2023, an estimated $1.1M increase.
  • Birchview Capital's biggest Q4 2023 reduction was Bristol-Myers Squibb, cutting an estimated $735K.
  • Birchview Capital fully exited Nektar Therapeutics in Q4 2023, selling an estimated $16.7K.
  • Birchview Capital's ten largest holdings make up 70% of its $128M portfolio in Q4 2023.
  • Birchview Capital opened 8 new positions and closed 1 in Q4 2023.
  • Birchview Capital's portfolio value rose 8.6% quarter-over-quarter to $128M.

Based on Birchview Capital's 13F filing for Q4 2023, filed 14 Feb 2024.